

Contents lists available at ScienceDirect

Data in Brief

journal homepage: www.elsevier.com/locate/dib

Data Article

Identification of new fisetin analogs as kinase inhibitors: Data on synthesis and anti-skin cancer activities evaluation



Tithi Roy^a, Samuel T. Boateng^a, Sergette Banang-Mbeumi^b, Pankaj K. Singh^{d,*}, Pratik Basnet^{a,c}, Roxane-Cherille N. Chamcheu^a, Federico Ladu^d, Isabel Chauvin^c, Vladimir S. Spiegelman^e, Ronald A. Hill^a, Konstantin G. Kousoulas^{f,g}, Bolni Marius Nagalo^h, Anthony L. Walker^b, Jean Fotieⁱ, Siva Murru^{c,*}, Mario Sechi^d, Jean Christopher Chamcheu^{a,*}

^a School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana - Monroe, Monroe, LA 71209-0497, USA

^b School of Clinical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71209-0497, USA

^c Chemistry, School of Sciences, University of Louisiana at Monroe, Monroe, LA 71209-0497, USA

^d Department of Chemistry and Pharmacy, University of Sassari, Via Vienna 2, 07100 Sassari, Italy

^e Department of Pediatrics, Division of Pediatric Hematology/Oncology, Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033-0850, USA

¹Division of Biotechnology and Molecular Medicine, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA

^g Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA

^h Division of Hematology and Medical Oncology, Mayo Clinic Hospital, Phoenix, AZ, 85054, USA

¹Department of Chemistry and Physics, Southeastern Louisiana University, Hammond, LA 70402-0878, USA

ARTICLE INFO

Article history: Received 6 January 2021 Revised 30 January 2021 Accepted 5 February 2021 Available online 10 February 2021

ABSTRACT

This article contains supplemental datasets of the recently published related research article "Synthesis, Inverse Docking-Assisted Identification and in vitro Biological Characterization of Flavonol-based Analogs of Fisetin as c-Kit, CDK2 and mTOR Inhibitors against Melanoma and Non-melanoma

DOI of original article: 10.1016/j.bioorg.2020.104595

* Corresponding author(s).

https://doi.org/10.1016/j.dib.2021.106858

E-mail addresses: maan.pankajsingh@gmail.com (P.K. Singh), murru@ulm.edu (S. Murru), chamcheu@ulm.edu (J.C. Chamcheu).

^{2352-3409/}Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

Keywords: Anticancer evaluation skin cancers fisetin analogs target prediction computational docking kinase activities melanoma and epidermoid carcinoma Skin Cancers" by Roy et al., [1]. It provides in-depth data not included in the original co-submission on the biophysical. molecular docking, and biological characterization of newly synthesized flavonol-based analogs of fisetin, a natural dietary small molecule with anticancer and anti-inflammatory properties. These synthetic small molecules were investigated as new, potential single and/or multi-kinase inhibitors of the cyclin-dependent kinase-2 (CDK2), receptor tyrosine kinases (c-KITs), and mammalian targets of rapamycin (mTOR) targets, potentially active against melanoma or nonmelanoma skin cancers. Furthermore, this data-in-brief article comprises additional sets of results on several aspects of the properties of the dual and multiple kinase inhibitor compounds' effects that were not presented in the associated article, including the activated targets that are dysregulated in skin cancers; the effects on markers of apoptosis; on colony formation; and in scratch wound healing assays. The study has identified a panel of novel fisetin analogs that are either single- or multi-kinase inhibitors, which may be further developed as active for the treatment of melanoma and nonmelanoma skin cancers. The dataset presented herein will be utilized for additional studies aiming to establish a biological platform to steer for predictive and experimental screening of novel flavonoids and analogs in relevant organoids, humanized animal models and in vivo disease models. The present results should also serve as a key stepping-stone towards enabling target-structure-based design, synthesis and initial testing of novel analogs or derivatives of fisetin. The current study may eventually lead to the development of safe, promising and preclinical candidate entities for treatment of skin and other forms of cancers as well as various other human diseases, which can possibly add to the general armamentarium of promising and safe drugs for health promotion.

> Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

Specifications Table

Subject Specific subject area Type of data	Chemistry and Biological sciences Medicinal Chemistry, Molecular Biology and Skin Cancer Research Table
How data were acquired	Dataset was collected as part of a synthesis and biophysical and biological characterization of novel flavonol derivatives of fisetin targeting specific kinases as anticancer agents [1]. The synthesized flavonol derivatives produced from microwave-assisted methods were purified and characterized using different spectroscopic and spectrometric techniques, such as ¹ H-NMR, ¹³ C-NMR, IR, GC-MS and HR-ESIMS [1]. Cell cultures were prepared, analyzed, and protein content was quantified using the BCA reagent assay (Thermo Fisher Scientific, Waltham, MA, USA). Protein electrophoresis: SDS-PAGE method (Protean 3 system, Bio-Rad, Hercules, CA, USA), followed by protein expression via the western blotting method, using the Bio-Rad analysis and imaging system as earlier described [1,2]. Analysis and graphs in the figures, including <i>in vitro</i> enzymatic kinase activities, western blot, scratch

wound assays, and colony formation were plotted using GraphPad PRISM program suite, version 8 (GraphPad Software, Inc., La Jolla, CA, USA), and molecular docking analysis [1,2]. <i>In silico</i> prediction of skin permeation, lipophilicity, absorption, distribution, metabolism, excretion (ADMET) properties of the analogs compared to the reference drug fisetin were performed and analyzed using the online SwissADME platform of the Swiss Institute of Bioinformatics [3].
Raw Analyzed
Data were collected at the end of each experiment; each experiment was repeated at least three times. The post experiment analysis parameters for consideration were: effect or no effect, with statistical consideration for any significant differences.
For western blot data, when exposed, faint and auto-exposed bands were obtained; the images were captured and analyzed using the Biorad image analysis software system. Densitometric data were collected, tallied and graphs were plotted to compare changes in the different treatment groups. The variations in protein and enzymes expressions in lysates and the differences in the proportion of colony sizes and numbers and wound closure areas were analyzed as in the associated research article [1] and as reported earlier [2]. Differences between samples treated with and without test compounds were measured and analyzed including protein and enzyme expression kinetics.
Institution: University of Louisiana-Monroe City/Town/Region: Monroe, Louisiana Country: USA
With the article
T Roy, ST. Boateng, SBanang-Mbeumi, PK. Singh, P Basnet, RN Chamcheu, F Ladu, I Chauvin, VS. Spiegelman, RA. Hill, KG Kousoulas, BM Nagalo, AL Walker, J Fotie, S Murru, M Sechi, JC Chamcheu. Synthesis, inverse-docking assisted targets identification, and in vitro biological characterization of potent fisetin analogs as c-Kit, CDK2 and mTOR inhibitors active against melanoma and non-melanoma skin cancers. Bioorg Chem. 2020 Dec 30;107:104595.

Value of the Data

- This additional dataset provides further insights into the characteristics of the different flavonol compounds synthesized as single or multi-kinase inhibitors. These compounds exhibited varying degrees of biophysical properties and biological effects on human skin cancer cell lines compared to minimal effects on untreated control groups. The data provide a clear picture of the range diversity of the effects of the different synthetic small molecular structures examined.
- This data-in-brief article contains results that can be used by scientists and researchers as a reference and guide towards future investigations that may explore the potential therapeutic diversity as well as repurposing of these compounds for treating other human diseases.
- This dataset may help to formulate new additional research hypotheses to explore the preclinical effects of these compounds toward ultimate clinical use. Also, scientists can utilize the data to improve drug discovery and development in anticancer and adjuvant therapies, alone or in combination with other known drugs.
- The work presented informs further investigations on the toxicological and safety profiles in lieu of their formulations alone or in combination with existing FDA approved drugs.

1. Data Description

This dataset article provides supplementary data to the associated research article by Roy et al., [1]. Fig. 1A-I reports the ¹H-NMR, ¹³C-NMR, and HR-<u>MS</u> data for the three most active

А.

B.



Fig. 1. Proton (¹H)-NMR and Carbon (¹³C)-NMR data for the three most active flavonols synthesized and characterized, namely, F9, F17 and F20. Data for all other flavonols are displayed in supplementary data 1.

71,1265

824926

12.0834

A. 3-Hydroxy-2-(3-methoxyphenyl)-7-methyl-4H-chromen-4-one (F9): 1H-NMR (400 MHz, CDCl₃)

- B. 3-Hydroxy-2-(3-methoxyphenyl)-7-methyl-4H-chromen-4-one (F9): ¹³C-NMR (100 MHz; CDCl₃)
- C. 3-Hydroxy-2-(3-methoxyphenyl)-7-methyl-4H-chromen-4-one (F9): HRMS (ESI)

rts per Mill

- D. 2-(3-Chlorophenyl)-6-fluoro-3-hydroxy-4H-chromen-4-one (F17): ¹H-NMR (400 MHz, CDCl₃)
- E. 2-(3-Chlorophenyl)-6-fluoro-3-hydroxy-4H-chromen-4-one (F17): ¹³C-NMR (100 MHz; CDCl₃)
- F. 2-(3-Chlorophenyl)-6-fluoro-3-hydroxy-4H-chromen-4-one (F17): HRMS (ESI)
- G. 2-(4-Bromophenyl)-3-hydroxy-6-methyl-8-nitro-4H-chromen-4-one (F20): ¹H-NMR (400 MHz, CDCl₃)
- H. 2-(4-Bromophenyl)-3-hydroxy-6-methyl-8-nitro-4H-chromen-4-one (F20): ¹³C-NMR (100 MHz; CDCl₃)
- I. 2-(4-Bromophenyl)-3-hydroxy-6-methyl-8-nitro-4H-chromen-4-one (F20): HRMS (ESI)





Species	Calc m/z	Formula	Species	m/z	Score	Diff(abs.	Mass
						ppm)	
M+	282.08866	$C_{17}H_{14}O_4$	(M+H)+	283.09629	98.15	0.94	282.08921
(M+H)+	283.09649						
(M+Na)+	305.07843						
(M+K)+	321.05237						

D.



Fig. 1. Continued

F.





Species	Calc m/z	Formula	Species	m/z	Score	Diff(abs. ppm)	Mass
M+	290.01405	C ₁₅ H ₈ Cl FO ₃	(M+H)+	291.02187	99.79	0.11	290.0146
(M+H)+	291.02188			•			
(M+Na)+	313.00382						
(M+K)+	328.97776						

Fig. 1. Continued

E.

G.



Η.



Fig. 1. Continued

8



Fig. 1. Continued

Table 1

Synthesis of Fisetin analogs via microwave-assisted Claisen-Schmidt condensation and modified Algar-Flynn-Oyamada (AFO) reactions.



analogs **F9**, **F17** and **F20** [1]. The general approach for the synthesis of Fisetin analogs and their structures provided in Table 1. The full/detailed properties of all 24 flavonol analogs synthesized are provided in Supplementary dataset 1 and their raw NMR data files provided in ASCII file format and the raw HR-MS data files in .txt format linked in the (HR-MS Raw Files) in the source repository. Table 2 reports the results from the *in silico* prediction of absorption, distribution, metabolism, excretion (ADME) of the three potent fisetin analogs in the associated article (1). All 24 analogs were predicted to possess improved cell penetration properties, with the three most active being in the order as F17>F9>F20, compared to fisetin, the parent natural compound. The table also shows the lipophilicity profile for which all compounds have good oral bio-absorption and intestinal absorption, but with less effective sub-lingual absorption. The Table 2 dataset presents on the three most active analogs, based on the log Kp value, is favored as follows F17>F9>F20 respectively, as compared to fisetin (F0). This reveals an important property for the skin pharmaceutical applications, an indication that each derivative has a better skin permeation (cm/s) ability than the parent compound, fisetin. Detailed raw ADME prediction data for all 24 flavonol compounds synthesized are displayed in supplementary dataset 2. Tables 3-14 report results of RMSD values obtained after Cross-docking/re-docking for the selection of PDB for EGFR (Table 2), c-Kit (Table 4), Akt (Table 5), MET (Table 6), MEK1 (Table 7), VEGFR1 (Table 8),

Table 2

In silico prediction of absorption, distribution, metabolism and excretion (ADME) for the most potent fisetin analogs, namely **F9, F17** and **F20**.

Physicochemical WWCode WWPion 286.24Pion 282.29Pion 200.67Pion 376.16MW286.24282.29290.67376.16WATOMATIC heavy atoms16101010Attomatic heavy atoms16161616Fraction Csp300.120.00101010#Rotable bonds121111#Hoond acceptors6411111MR76.0181.474.9191.4391.43MUOP1.52.982.742.4692.62MUOCP1.52.982.742.4292.62MUOCP2.034.514.542.4292.62MUOCP2.031.573.763.923.763.92VaterESOL Solubility (mg/ml)1.2761.503.093.653.55-03ESOL Solubility (mg/ml)1.276-012.026-059.0409.040Atl Solubility (mg/ml)1.276-012.026-059.0509.050Atl Cas-3.93-4.37-4.51-5.62Atl Cas-3.93-4.34-6.613.051Atl Cas-3.93-4.54-5.623.051Atl Cas-3.93-6.07-6.44-6.11Atl Cas-3.94-0.011.56-043.051Solubility (mg/ml)1.376-022.480.0610.0161Atl Cas-3.93-6.17-6.	Properties	Cmpd#	1	10	18	21
Physicochemical #ysicochemical #raction Csp3286.24282.29290.67376.16Physicochemical #raction Csp316161616Fraction Csp300.1200.06#Rotatable bonds1212#Rotatable bonds6445#Hoond denors6411MR76.0181.474.9191.43MR76.0181.474.9191.43MR76.0181.474.9192.62MUOCP1.572.982.742.46MUOCP1.973.773.763.92MUOCP-0.031.572.571.53Silicos-TT Log P0.301.572.571.53Solubility(Dog S-3.53-4.54-5.02Solubility1.553.093.65-0.32Solubility1.27E.012.02E-028.44E-033.55E-03Solubility1.37E-033.07E-052.90E-05Solubility3.37E-038.61E-043.01UeMit Log S-3.93-4.3-4.51-5.64All Solubility (mg/m1)1.37E-022.41E-038.61E-04All Solubility (mg/m1)1.37E-022.45E-041.05E-04Jali Solubility (mg/m1)1.37E-022.45E-041.05E-04All ClassSolubleSolubleSolubleSolubleSilicos-TT LogSw-3.82-6.07-6.44-6.611All Class <t< th=""><th></th><th>Code</th><th>F0</th><th>F9</th><th>F17</th><th>F20</th></t<>		Code	F0	F9	F17	F20
Physicochemical #Aromatic heavy atoms21212023#Aromatic heavy atoms16161616Faction (Sp300.1200.06#Rotatable bonds1212#H-bond acceptors6445#H-bond acceptors6445#H-bond acceptors6445#H-bond acceptors76.0181.474.9191.43TPSA111.1359.6750.4496.26Lipophilicity1100P2.283.483.843.84LiDOP2.283.483.844.14MCOP2.283.483.844.14MCOP2.301.572.571.53Silicos-FT Log P2.031.612.90E-059.45E-06ESOL Solubility (mg/h)1.27E-012.02E-028.44E-033.55E-30ESOL Solubility (mg/h)1.27E-012.02E-028.44E-033.55E-30ESOL Class-3.35-4.152.90E-059.45E-06ESOL Class-3.37-4.51-5.623.07E-03Ali Solubility (mg/h)1.37E-021.41E-028.94E-03Ali Solubility (mg/h)1.38E-045.01E-033.07E-03Ali Solubility (mg/h)1.36E-042.36E-04-6.11Ali Solubility (mg/h)1.50E-042.48E-04-6.11Ali Solubility (mg/h)1.50E-042.48E-04-6.11Silicos-FT Solubility (mg/h)1.50E-04 <t< th=""><th></th><th>MW</th><th>286.24</th><th>282.29</th><th>290.67</th><th>376.16</th></t<>		MW	286.24	282.29	290.67	376.16
Aromatic heavy atoms16161616Fraction Csp300.1200.060#Rotatable bonds1212#H-bond decores6445#H-bond decores4111MR76.018.1474.9191.43TPSA111.1359.6750.44492.62Lipophilicity110CP1.52.982.742.46XLOCP31.573.703.763.92WLOCP2.283.484.384.14MLOCP2.034.034.572.48Solubility2.034.034.572.48Consensus Log P1.553.093.62.91Solubility1.27E-012.02E-028.44E-033.55E-03Solubility5.01ubility (mg/ml)1.27E-012.02E-028.44E-03Solubility5.01ubility (mg/ml)3.37E-021.41E-028.94E-04Ali Solubility (mg/ml)1.37E-041.41E-052.90E-053.01UeAli Solubility (mg/ml)1.37E-041.41E-052.90E-063.00E-053.00E-05Ali Solubility (mg/ml)1.37E-045.00E-053.07E-072.91E-06Ali Solubility (mg/ml)1.37E-043.01E-073.61E-073.61E-07Ali Solubility (mg/ml)1.37E-045.00E-053.07E-075.00E-07Silice-rT LogSw-3.82-6.07-6.47-6.07Silice-rT Solubility (mg/ml)1.50E-048	Physicochemical	#Heavy atoms	21	21	20	23
Fraction Csp300.1200.06#Rotatable bonds1212#Rotatable bonds6445#H-bond dacceptors6411MR76.0181.474.9191.43TPSA11.1359.6750.4496.26Lipophilicity1.502.982.742.46MLOCP1.572.982.742.46MLOCP1.572.983.763.92WLOCP2.283.484.384.14MLOCP2.034.034.542.48Consensus Log P1.553.093.62.91SolubilityESOL Solubility (mg/ml)1.27E-012.02E-028.44E-03ESOL Solubility (mg/ml)1.27E-012.02E-028.44E-033.55E-03SolubiliSolubili7.16E-053.07E-053.07E-053.92E-03Ali Log S-3.93-4.3-4.51-5.64Ali Solubility (mg/ml)3.37E-021.41E-028.94E-038.61E-04Ali Solubility (mg/l)1.38E-045.00E-053.07E-053.07E-05Ali Solubility (mg/l)1.38E-043.61E-048.61E-04Ali Solubility (mg/l)1.38E-043.61E-042.98E-04Silicos-TT Solubility (mg/ml)1.28E-022.43E-041.05E-04Silicos-TT Solubility (mg/l)1.28E-022.43E-043.61E-04Silicos-TT Solubility (mg/l)4.29E-022.43E-043.61E-04Silicos-T	•	#Aromatic heavy atoms	16	16	16	16
#Rotatable bonds1212#H-bond decors6445#H-bond decors6411Importation of the decord of the d		Fraction Csp3	0	0.12	0	0.06
#H-bond acceptors6445#H-bond doors4111MR76.0181.474.9191.43IpophilicityTPSA111.1359.6750.4496.26Lipophilicity160CP1.572.382.742.46MLOCP31.973.373.763.923.92WUOCP2.283.484.384.14MLOCP-0.031.572.571.53Silicos-IT Log P2.034.034.542.48Consensus Log P1.553.94-4.54-5.02solubilityESOL Solubility (mg/ml)1.27E-012.02E-028.44E-033.55E-03solubicSolubicModeratelyModeratelyModeratelysolubicESOL Class-3.93-4.3-4.51-5.64Ali Solubility (mg/ml)3.37E-028.44E-033.51E-06Ali Solubility (mg/ml)1.37E-021.41E-028.94E-038.01E-04Ali Solubility (mg/ml)1.38E-0650/UblemoderatelyModeratelyAli Solubility (mg/ml)1.37E-021.41E-028.94E-038.01E-04Silicos-IT Solubility (mg/ml)1.28E-041.05E-042.29E-06Ali ClassSolubleModeratelyModeratelyModeratelySilicos-IT Solubility (mg/ml)1.28E-041.05E-042.98E-04Silicos-IT Solubility (mg/ml)1.28E-041.05E-042.98E-04Silicos-IT Solubility (mg/ml)1.28E-06Soluble		#Rotatable bonds	1	2	1	2
#H-bond donors4111MR76.0181.474.9191.43TPSA111.1359.6750.4496.26ILOOP15.52.982.742.46XLOGP31.973.373.763.92WLOGP2.283.484.344.14MLOGP-0.031.572.571.53Silicos-TT Log P2.034.034.542.48Consensus Log P1.553.093.62.91VaterESOL Solubility (mg/ml)1.27E-012.02C-028.44E-03ESOL Solubility (mg/l)1.27E-012.02C-028.44E-033.55E-03ESOL Solubility (mg/l)1.27E-012.02C-028.44E-033.55E-03ESOL Class-3.33-4.15-5.643.01E-04Ali Log S-3.93-4.3-4.51-5.64Ali Solubility (mg/ml)1.37E-021.41E-028.94E-038.61E-04Ali Solubility (mg/ml)1.37E-022.48E-073.07E-052.29E-06Ali Class-3.93-6.07-6.44-6.11Silicos-TT Solubility (mg/ml)1.37E-042.89E-042.89E-04Silicos-TT Solubility (mg/ml)1.50E-042.89E-04Silicos-TT Solubility (mg/ml)1.50E-042.89E-04Silicos-TT Solubility (mg/ml)1.50E-042.89E-04Silicos-TT Solubility (mg/ml)1.50E-048.61E-07Silicos-TT Solubility (mg/ml)1.50E-048.61E-07Silicos-TT Solubility (mg/ml)1		#H-bond acceptors	6	4	4	5
MR TPSA76.081.474.9191.43LipophilicityTPSA11.1359.6750.4496.26LipophilicityIIGOP1.52.982.742.46KLOCP31.973.373.763.92WLOCP2.283.484.384.14MLOCP-0.031.572.571.53Silicos-IT Log P2.034.034.542.48Consensus Log P1.553.093.62.91SolubilityESOL Solubility (moll)1.27E-012.02E-028.44E-033.55E-03SolubilitySolubility (moll)4.43E-047.16E-052.30E-059.45E-06SolubilitySolubility (moll)4.43E-047.16E-053.00Le9.45E-06Ali Solubility (mg/ml)1.37E-02SolubilisolublesolublesolubleAli Solubility (mg/ml)3.37E-02SolublesolublesolublesolubleAli Solubility (mg/ml)1.38E-045.022.29E-053.07E-053.07E-052.29E-06Ali Solubility (mg/ml)1.38E-045.01C3.07E-053.07E-052.29E-06Ali Solubility (mg/ml)1.35E-044.81E-073.61E-073.61E-07Silicos-IT Solubility (mg/ml)1.50E-042.89E-04solublesolubleSilicos-IT Solubility (mg/ml)1.50E-048.61E-04-6.11Silicos-IT Solubility (mg/ml)1.50E-048.61E-073.61E-073.61E-07Silicos-IT SolubilityNoNo <td< th=""><th></th><th>#H-bond donors</th><th>4</th><th>1</th><th>1</th><th>1</th></td<>		#H-bond donors	4	1	1	1
Interm TSA10.010.040.449.6.26LipophilicityiLOCP1.52.982.742.46KUOCP1.573.373.763.92WLOCP2.283.484.384.14MLOCP-0.031.572.571.53Silicos-IT Log P2.034.034.542.48Consensus Log P1.553.093.62.91WaterESOL Solubility (mg/ml)1.27E-012.02E-028.44E-033.55E-03ESOL Solubility (mg/ml)1.27E-012.02E-028.44E-033.55E-03ESOL Solubility (mg/ml)3.37E-021.41E-048.94E-038.61E-04Ali Log S-3.93-4.3-4.51-5.64Ali Solubility (mg/ml)3.37E-021.41E-028.94E-038.61E-04Ali Solubility (mg/ml)3.37E-021.41E-028.94E-038.61E-04Ali Solubility (mg/ml)3.37E-021.41E-028.94E-038.61E-04Ali Solubility (mg/ml)3.37E-021.41E-028.94E-042.99E-04Silicos-TT Solubility (mg/ml)1.32E-022.43E-041.05E-042.89E-04Silicos-TT Solubility (mg/ml)1.50E-048.61E-073.61E-077.69E-07Silicos-TT Solubility (mg/ml)1.50E-048.61E-073.61E-077.69E-07Silicos-TT Solubility (mg/ml)1.50E-048.61E-073.61E-077.69E-07Silicos-TT Solubility (mg/ml)1.50E-048.61E-073.61E-077.69E-07Silicos-TT Solubility		MP	76.01	81 <i>1</i>	7/ 01	01/13
LipophilicityITSM11.1.133.0030.04490.020Lipophilicity11.071.373.373.763.92WLOCP1.572.584.484.384.14MLOCP-0.031.572.571.53Silicos-IT Log P2.034.034.542.48Consensus Log P1.553.093.62.91WaterESOL Solubility (mg/ml)1.27E-012.02E-028.44E-03SolubilityESOL Solubility (mg/ml)4.32E-047.16E-059.45E-06ESOL ClassSolubleModeratelyModeratelyModeratelyAli Log S-3.39-4.3-4.51-5.64Ali Solubility (mg/ml)3.37E-021.41E-028.94E-038.61E-04Ali Solubility (mg/ml)3.37E-021.41E-028.94E-038.61E-04Ali Solubility (mg/ml)3.37E-021.41E-028.94E-038.61E-04Ali Solubility (mg/ml)3.37E-021.41E-028.94E-038.61E-04Ali Solubility (mg/ml)1.32E-043.07E-052.29E-06Ali ClassSolubleModeratelyModeratelyModeratelySilicos-IT Solubility (mg/ml)4.29E-022.43E-041.05E-042.89E-04Silicos-IT Solubility (mg/ml)4.29E-022.43E-041.05E-042.89E-04Silicos-IT Solubility (mg/ml)4.29E-022.43E-041.05E-042.89E-04Silicos-IT Solubility(mol1)1.50E-048.61E-073.61E-07Silicos-IT Class <t< th=""><th></th><th>TDCA</th><th>111 12</th><th>50.67</th><th>50.44</th><th>06.26</th></t<>		TDCA	111 12	50.67	50.44	06.26
IppinintertyLtor1.32.362.742.40XLOCP1.973.373.763.92WLOCP2.283.484.384.14MLOCP2.031.572.571.53Silicos-IT Log P2.034.034.542.48Consensus Log P1.553.093.62.91WaterESOL Solubility (mg/ml)1.27E-012.02E-028.44E-033.55E-03ESOL Solubility (mg/ml)1.27E-012.02E-028.44E-033.55E-03ESOL Solubility (mg/ml)4.43E-047.16E-052.90E-059.45E-06ESOL Solubility (mg/ml)3.37E-021.41E-04SolublesolubleAli Log S-4.3-4.51-5.6441iAli Solubility (mg/ml)3.37E-021.41E-038.61E-04Ali Solubility (mg/ml)1.38E-045.00E-053.07E-052.29E-06Ali ClassSolubleSolublesolublesolublesolubleSilicos-IT Solubility (mg/ml)4.29E-022.43E-041.05E-042.89E-04Silicos-IT Solubility (mg/ml)1.50E-048.61E-073.61E-077.69E-07Silicos-IT Solubility (mg/ml)1.50E-048.61E-073.61E-077.69E-07Silicos-IT Solubility (mg/ml)1.50E-048.61E-073.61E-077.69E-07Silicos-IT Solubility (mg/ml)1.50E-048.61E-073.61E-077.69E-07Silicos-IT Solubility (mg/ml)1.50E-048.61E-073.61E-077.69E-07Silicos-IT Solubi	Linonhilicity	HOCD	111.15	39.07	2 74	90.20 2.46
AUGUPS1.975.375.373.703.32W10CP2.283.484.384.14MLOCP-0.031.572.571.53Silicos-IT Log P2.034.034.542.48Consensus Log P1.553.093.62.91SolubilityESOL Log S-3.35-4.15-4.54-5.02SolubilityESOL Solubility (mg/ml)1.27E-012.02E-028.44E-033.55E-03ESOL Solubility (mg/ml)4.43E-047.16E-052.90E-059.45E-06ESOL ClassSolubleSolublesolublesolublesolubleAli Solubility (mg/ml)3.37E-021.41E-028.94E-038.61E-04Ali Solubility (mg/ml)1.32E-045.00E-053.07E-052.29E-06Ali ClassSolubleModeratelyModeratelyModeratelyAli Solubility (mg/ml)1.32E-022.43E-041.05E-042.89E-04Silicos-IT Solubility (mg/ml)1.50E-048.61E-073.07E-077.69E-07Silicos-IT Solubility (mg/ml)4.29E-022.43E-041.05E-042.89E-04Silicos-IT Solubility (mg/ml)1.50E-048.61E-073.61E-073.61E-07Silicos-IT Solubility (mg/ml)1.50E-048.61E-073.61E-073.61E-07Silicos-IT Solubility (mg/ml)1.62E-059.65E9.00E9.00ESolubleSolubleNoNoNoNoNoPharmaceuticsGl absorptionHighHighHigh <t< th=""><th>Lipopiniicity</th><th></th><th>1.5</th><th>2.90</th><th>2.74</th><th>2.40</th></t<>	Lipopiniicity		1.5	2.90	2.74	2.40
WLOLF2.263.484.394.14MLOCP-0.031.572.571.53Silicos-IT Log P2.034.034.542.48Consensu Log P1.553.093.62.91solubilityESOL Log S-3.35-4.15-4.54-5.02solubilityESOL Solubility (mg/ml)1.27E-012.02E-028.44E-033.55E-03ESOL Solubility (mg/ml)4.43E-047.16E-052.90E-059.45E-06ESOL ClassSolubleModeratelyModeratelyModeratelyAli Log S-3.93-4.3-4.51-5.64Ali Solubility (mg/ml)3.78E-021.41E-028.94E-038.61E-04Ali Solubility (mg/nl)1.18E-045.00E-053.07E-052.29E-06Ali ClassSolubleModeratelyModeratelyModeratelyModeratelySolubleSolubleSolubleSolubleSilicos-TT Solubility (mg/ml)4.29E-022.43E-043.61E-07Silicos-TT Solubility (mg/ml)4.29E-022.43E-043.61E-07Silicos-TT Solubility (mg/ml)4.29E-022.43E-040.01DeSilicos-TT ClassSolublesolublesolubleSolubleSolubleNoNoNoPharmaceuticsG1 absorptionHighHighHighBB permeantNoYesYesNoCYP2C9 inhibitorYesYesNoNoCYP2C9 inhibitorYesYesNoNoCYP2		ALUGPS	1.97	2.27	3.70	5.92
MLOCP-0.031.572.571.53Silicos-IT Log P2.034.034.542.48Consensus Log P1.553.093.62.91WaterESOL Solubility (mg/ml)1.27c-012.02t-028.44t-033.55E-03SolubilityESOL Solubility (mg/ml)4.43E-047.16E-052.90E-059.45E-06ESOL ClassSolubleModeratelyModeratelySolubleSolubleSolubleSolubleAli Log S-3.93-4.3-4.51-5.64Ali Solubility (mg/ml)3.37E-021.41E-028.94E-038.61E-04Ali Solubility (mg/ml)3.37E-021.41E-028.94E-038.61E-04Ali ClassSolubleSolubleModeratelyModeratelySilicos-IT LogSw-3.82-6.075.01E-075.84E-038.61E-043.01E-072.98E-06Silicos-IT Solubility (mg/ml)4.29E-022.43E-041.05E-042.89E-04Silicos-IT Solubility (mg/ml)1.50E-048.61E-073.61E-077.69E-07Silicos-IT CalssSolublePoorlyPoorlyPoorlyPoorlyPharmaceuticsG absorptionHighHighHighHighHighBBB permeantNoNoNoNoNoPoorlyCYP2C9 inhibitorNoYesYesNoYesYesCYP2C9 inhibitorNoYesYesNoPoorlyPoorlyCYP2C9 inhibitorNoNoNoNoQiQi		WLOGP	2.28	3.48	4.38	4.14
Suitcos-II Log P2.034.034.542.48WaterESOL Log S-3.35-4.15-4.54-5.02solubilityESOL Solubility (mg/ml)1.27E-012.02E-028.44E-033.55E-03ESOL Solubility (mol/l)4.43E-047.16E-052.90E-059.45E-06ESOL ClassSolubleModeratelyModeratelyModeratelyAli Log S-3.93-4.3-4.51-5.64Ali Solubility (mg/ml)3.37E-021.41E-028.94E-038.61E-04Ali Solubility (mg/ml)3.37E-021.41E-028.94E-038.61E-04Ali Solubility (mg/ml)1.18E-045.00E-053.07E-052.29E-06Ali ClassSolublesolublesolublesolubleSilicos-IT Solubility (mg/ml)1.28E-041.05E-042.89E-04Silicos-IT Solubility (mg/ml)4.29E-022.43E-041.05E-042.89E-04Silicos-IT ClassSolublePoorlysolublesolubleSolubleGI absorptionHighHighHighBBB permeantNoNoNoNoNoCYP2C9 inhibitorYesYesNoNoCYP2C9 inhibitorYesYesNoNoCYP2C9 inhibitorNoNo000CYP2C9 inhibitorYesYesNoNoCYP2C9 inhibitorNoNoNoNoNoCYP2C9 inhibitorNo0000Egan #violations0 <th></th> <th>MLOGP</th> <th>-0.03</th> <th>1.57</th> <th>2.57</th> <th>1.53</th>		MLOGP	-0.03	1.57	2.57	1.53
WaterConsensus Log P1.553.093.62.91solubilityESOL Log S-3.35-4.15-4.54-5.02solubilityESOL Solubility (mol/l)1.27E-012.02E-028.44E-033.55E-03ESOL ClassSolubleModeratelyModeratelyModeratelySolubleSolubleAli Log S-3.93-4.3-4.51-5.64Ali Solubility (mol/l)1.18E-045.00E-053.07E-052.29E-06Ali Solubility (mol/l)1.18E-045.00E-053.07E-052.29E-06Ali ClassSolubleModeratelyModeratelyModeratelysolubleSolubleSolubleSolublesolubleAli ClassSolubleModeratelyModeratelySolublesolubleSolublity (mol/l)1.50E-048.61E-073.61E-04Ali ClassSolubleSolublesolublesolubleSilicos-IT LogSw-3.82-6.07-6.44-6.11Silicos-IT Solubility (mol/l)1.50E-048.61E-073.61E-07Silicos-IT Solubility (mol/l)1.50E-048.61E-073.61E-07Silicos-IT Solubility (mol/l)1.50E-048.61E-073.61E-07Silicos-IT Solubility (mol/l)1.50E-048.61E-073.61E-07Silicos-IT Solubility (mol/l)1.50E-048.61E-073.61E-07Silicos-IT Solubility (mol/l)1.50E-048.61E-073.61E-07Silicos-IT SolubilityNoYesYesYesYegYegYes		Silicos-II Log P	2.03	4.03	4.54	2.48
WaterESOL Log S-3.35-4.15-4.54-5.02solubilityESOL Solubility (mg/ml)1.27E-012.02E-028.44E-033.55E-03ESOL Solubility (mol/l)4.43E-047.16E-052.90E-059.45E-06ESOL ClassSolubleModeratelyModeratelyModeratelyAll Log S-3.93-4.3-4.51-5.64All solubility (mg/ml)3.37E-021.41E-028.94E-038.61E-04All Solubility (mg/nl)1.18E-045.00E-053.07E-052.29E-06Ali ClassSolublesolublesolublesolubleSilicos-IT LogSw-3.82-6.07-6.44-6.11Silicos-IT Solubility (mg/ml)4.29E-022.43E-041.05E-072.89E-04Silicos-IT Solubility (mg/ml)4.29E-022.43E-041.05E-072.89E-04Silicos-IT Solubility (mg/ml)4.29E-022.43E-041.05E-072.89E-04Silicos-IT Solubility (mg/ml)4.29E-022.43E-041.05E-072.89E-04Silicos-IT Solubility (mg/ml)4.29E-022.43E-041.05E-072.89E-04Silicos-IT Solubility (mg/ml)4.29E-022.43E-041.05E-072.99E-06PharmaceuticsGI absorptionHighHighHighHighBBB permeantNoYesYesYesNoVP212 inhibitorYesYesYesNoYesCYP212 inhibitorYesYesYesYesYesCYP214 inhibitorYesYes<		Consensus Log P	1.55	3.09	3.6	2.91
solubilityESOL Solubility (maj/ml)1.27E-012.02E-028.44E-033.35E-03ESOL Solubility (mol/l)4.43E-047.16E-052.90E-059.45E-06ESOL ClassSolubleModeratelyModeratelyModeratelyAli Log S-3.93-4.3-4.51-5.64Ali Solubility (mg/ml)3.37E-021.41E-028.94E-038.61E-04Ali Solubility (mg/ml)1.18E-045.00E-053.07E-052.29E-06Ali ClassSolubleModeratelyModeratelyModeratelysolublesolublesolublesolublesolubleSilicos-IT LogSw-3.82-6.07-6.44-6.11Silicos-IT Solubility (mg/ml)4.29E-022.43E-041.05E-042.89E-04Silicos-IT Solubility (mg/ml)1.50E-048.61E-073.61E-077.69E-07Silicos-IT Solubility (mg/ml)1.50E-048.61E-073.61E-077.69E-07Silicos-IT Solubility (mg/ml)1.50E-048.61E-073.61E-077.69E-07Silicos-IT Solubility (mg/ml)1.50E-048.61E-073.61E-077.69E-07Silicos-IT Solubility (mg/ml)1.50E-048.61E-073.61E-077.69E-07Silicos-IT Solubility (mg/ml)1.50E-048.61E-073.61E-077.69E-07Silicos-IT ClassNoNoYesYesYesPgp substrateNoNoNoNoNoCYP2C19 inhibitorYesYesYesYesPgo inhibitorYesYesYe	Water	ESOL Log S	-3.35	-4.15	-4.54	-5.02
ESOL Solubility (mol/l)4.43E-047.16E-052.90E-059.45E-06ESOL ClassSolubleModeratelyModeratelySolublesolublesolublesolublesolublity (mg/ml)3.37E-021.41E-028.94E-038.61E-04Ali Solubility (mg/ml)1.37E-021.41E-028.94E-038.61E-04Ali Solubility (mol/l)1.18E-045.00E-053.07E-052.29E-06Ali ClassSolubleModeratelyModeratelyModeratelySilicos-IT Solubility (mg/ml)4.29E-022.43E-041.05E-042.89E-04Silicos-IT Solubility (mg/ml)1.50E-048.61E-073.61E-077.69E-07Silicos-IT classSolublePoorlyPoorlyPoorlyPharmaceuticsGl absorptionHighHighHighBBB permeantNoYesYesNoNoCYP1A2 inhibitorYesYesYesNoNoCYP2C9 inhibitorNoYesYesNoNoCYP220 inhibitorYesYesYesYesNoCYP220 inhibitorYesYesNo000Cyp214 inhibitorYesYesYesYesNoNoCYP220 inhibitorYesYesYesYesYesYesDrug-likenessLipinski #violations00000Gl absorption-6.65-5.63-5.4-5.81100Drug-likenessFiviolations <t< th=""><th>solubility</th><th>ESOL Solubility (mg/ml)</th><th>1.27E-01</th><th>2.02E-02</th><th>8.44E-03</th><th>3.55E-03</th></t<>	solubility	ESOL Solubility (mg/ml)	1.27E-01	2.02E-02	8.44E-03	3.55E-03
ESOL ClassSolubleModerately solubleModerately solubleModerately solubleModerately 		ESOL Solubility (mol/l)	4.43E-04	7.16E-05	2.90E-05	9.45E-06
NoteSolubleSolubleSolubleAli Log S-3.93-4.3-4.51-5.64Ali Solubility (mg/ml)3.37E-021.41E-028.94E-038.61E-04Ali Solubility (mol/l)1.18E-045.00E-053.07E-052.29E-06Ali ClassSolubleModeratelyModeratelysolublesolublesoluble-6.07-6.64-6.11Silicos-IT Solubility (mg/ml)4.29E-022.43E-041.05E-042.89E-04Silicos-IT Solubility (mg/ml)1.50E-048.61E-073.61E-077.69E-07Silicos-IT CalssSolublePoorlyPoorlyPoorlyPoorlyPharmaceuticsG absorptionHighHighHighHighBBB permeantNoYesYesNoNoPharmaceuticsG labsorptionNoYesYesNoCYP2C9 inhibitorNoYesYesNoYesCYP2C9 inhibitorYesYesYesNoYesCYP2D6 inhibitorYesYesYesYesYesCYP2D6 inhibitorYesYesYesNoOOCYP2D6 inhibitorYesYesYesNoYesCYP2D6 inhibitorYesYesYesYesYesCYP2D6 inhibitorYesYesNoOOCYP2D6 inhibitorYesYesYesYesYesLipinski #violationsOOOOOGhose #violati		ESOL Class	Soluble	Moderately	Moderately	Moderately
Aii Log S-3.93-4.3-4.51-5.64Ali Solubility (mg/ml)3.37E-021.41E-028.94E-038.61E-04Ali Solubility (mol/l)1.18E-045.00E-053.07E-052.29E-06Ali ClassSolubleModeratelysolublesolubleSilicos-TT LogSw-3.82-6.07-6.44-6.11Silicos-TT Solubility (mg/ml)4.29E-022.43E-041.05E-042.89E-04Silicos-TT Solubility (mg/ml)1.50E-048.61E-073.61E-077.69E-07Silicos-TT Solubility (mol/l)1.50E-048.61E-073.61E-077.69E-07Silicos-TT Solubility (mol/l)1.50E-048.61E-073.61E-073.61E-07Silicos-TT Solubility (mol/l)1.50E-048.61E-073.61E-073.61E-07Silicos-TT Solubility (mol/l)1.50E-048.61E-073.01blesolublesolublesolublesolublesolublesolublesolublePharmaceuticsGI absorptionHighHighHighHighBBB permeantNoYesYesNoNoPgg substrateNoNoYesNoNoCVP2C9 inhibitorYesYesNoNoYesCVP2D6 inhibitorYesYesNoNoNoCVP2D6 inhibitorYesYesYesYesYesLog Kp (cm/s) (Skin permeation)00000Gose #violations00000Muegge #violatio				soluble	soluble	soluble
Ali Solubility (mg/ml)3.37E-021.41E-028.94E-038.61E-04Ali Solubility (mol/l)1.18E-045.00E-053.07E-052.29E-06Ali ClassSolubleNoderatelyModeratelyModeratelysolublesolublesolublesolublesolubleSilicos-TT LogSw-3.82-6.07-6.44-6.11Silicos-TT Solubility (mg/ml)4.29E-022.43E-041.05E-042.89E-04Silicos-TT Solubility (mg/l)1.50E-048.61E-073.61E-077.69E-07Silicos-TT ClassSolublePoorlyPoorlypoorlysolublePharmaceuticsGl absorptionHighHighHighHighBBB permeantNoYesYesNoNoPgp substrateNoNoNoNoYesCYP2C19 inhibitorYesYesYesYesCYP2C2 inhibitorYesYesYesYesCYP2C3 inhibitorYesYesYesYesCYP2C4 inhibitorYesYesYesYesCYP2C5 inhibitorNo0000CYP2C4 inhibitorYesYesYesYesIpinski #violations00000Gl Kp (cm/s) (Skin permeation)-6.65-5.63-5.4-5.81Drug-likenessIpinski #violations0000Gl Kp (cm/s) (Skin permeation)0.6.550.550.550.55Gl Rose #violations0		Ali Log S	-3.93	-4.3	-4.51	-5.64
Ali Solubility (mol/l)1.18E-045.00E-053.07E-052.29E-06Ali ClassSolubleSolublesolublesolublesolubleSilicos-IT LogSw-3.82-6.07-6.44-6.11Silicos-IT Solubility (mg/ml)4.29E-022.43E-041.05E-042.89E-04Silicos-IT Solubility (mg/nl)1.50E-048.61E-073.61E-077.69E-07Silicos-IT classSolublePoorlyPoorlyPoorlyPoorlyPharmaceuticsGI absorptionHighHighHighHighHighBBB permeantNoYesYesNoNoPg substrateNoNoNoNoNoNoCYP2C19 inhibitorYesYesYesNoNoCYP2C19 inhibitorYesYesYesNoNoDrug-likenessLipinski #violations00000Bioavailability Score0.550.550.550.550.55PAINS #alerts100000Leadlikeness #violations000000Bioavailability Score0.550.550.550.550.550.55PAINS #alerts100122PAINS #alerts10002PAINS #alerts10012PAINS #alerts10002PAINS #alerts10 <t< th=""><th></th><th>Ali Solubility (mg/ml)</th><th>3.37E-02</th><th>1.41E-02</th><th>8.94E-03</th><th>8.61E-04</th></t<>		Ali Solubility (mg/ml)	3.37E-02	1.41E-02	8.94E-03	8.61E-04
Ali ClassSolubleModerately solubleModerately solubleModerately solubleModerately solubleModerately solubleSilicos-IT Solubility (mg/ml)-3.82-6.07-6.44-6.11Silicos-IT Solubility (mg/ml)1.50E-022.43E-041.05E-042.89E-04Silicos-IT Solubility (mol/l)1.50E-048.61E-073.61E-077.69E-07Silicos-IT classSolublePoorlyPoorlyPoorlyPharmaceuticsGl absorptionHighHighHighHighBBB permeantNoYesYesNoPgp substrateNoNoNoNoNoCYP2C19 inhibitorYesYesYesNoCYP2C19 inhibitorYesYesYesNoCYP2C9 inhibitorYesYesYesYesCYP2A1 inhibitorYesYesYesYesDrug-likenessLipinski #violations000Ghow #violations0000Ghow #violations0000Ghow #violations0000Bioavailability Score0.550.5550.5550.555PAINS #alerts1002Leadlikeness #violations0012Alisterts1012Alisterts1012Alisterts1012Alisterts1012		Ali Solubility (mol/l)	1.18E-04	5.00E-05	3.07E-05	2.29E-06
Silicos-IT LogSw-3.82-6.07-6.44-6.11Silicos-IT Solubility (mg/ml)4.29E-022.43E-041.05E-042.89E-04Silicos-IT Solubility (mol/l)1.50E-048.61E-073.61E-077.69E-07Solubility (mol/l)1.50E-048.61E-073.61E-077.69E-07PharmaceuticsGl absorptionHighHighHighHighBBB permeantNoYesYesNoPgp substrateNoNoNoNoNoCYP2C19 inhibitorYesYesYesNoCYP2C9 inhibitorNoYesYesYesCYP2D6 inhibitorYesYesNoNoCYP2D6 inhibitorYesYesYesYesCYP2D6 inhibitorYesYesYesYesDrug-likenessItipiski #violations000Ghose #violations0000Bioavailability Score <td< th=""><th></th><th>Ali Class</th><th>Soluble</th><th>Moderately soluble</th><th>Moderately soluble</th><th>Moderately soluble</th></td<>		Ali Class	Soluble	Moderately soluble	Moderately soluble	Moderately soluble
Silicos-IT Solubility (mg/ml)4.29E-022.43E-041.05E-042.89E-04Silicos-IT Solubility (mol/l)1.50E-048.61E-073.61E-077.69E-07Silicos-IT classSolublePoorlyPoorlyPoorlysolubleSolubleSolubleSolubleSolubleSolublePharmaceuticsGl absorptionHighHighHighHighBBB permeantNoYesYesNoNoPgp substrateNoNoNoNoNoCYP2C19 inhibitorYesYesYesNoNoCYP2C9 inhibitorYesYesNoNoYesCYP2C9 inhibitorYesYesNoNoNoCYP2C9 inhibitorYesYesNoNoNoCYP2C9 inhibitorYesYesNoNoNoCYP2C9 inhibitorYesYesNoNoNoCYP2C9 inhibitorYesYesYesYesYesCYP2C9 inhibitorYesYesNoNoNoCYP3A4 inhibitorYesYesYesNoNoChose #violations00000Glose #violations00000Bioavailability Score0.550.550.550.550.55PAINS #alerts1002Leadlikeness #violations0012Brenk #alerts1012 <t< th=""><th></th><th>Silicos-IT LogSw</th><th>-3.82</th><th>-6.07</th><th>-6.44</th><th>-6.11</th></t<>		Silicos-IT LogSw	-3.82	-6.07	-6.44	-6.11
Silicos-IT Solubility (mol/l)1.50E-04 Soluble8.61E-07 Poorly3.61E-07 Poorly7.69E-07 PoorlyPharmaceuticsGl absorption BBB permeantHigh NoHigh YesHigh YesHigh YesHigh 		Silicos-IT Solubility (mg/ml)	4.29E-02	2.43E-04	1.05E-04	2.89E-04
Silicos-IT classSolublePoorly solublePoorly solublePoorly solublePoorly solublePharmaceuticsGl absorptionHighHighHighHighHighBBB permeantNoYesYesNoPgp substrateNoNoNoNoNoCYP1A2 inhibitorYesYesYesYesCYP2C9 inhibitorNoYesYesNoCYP2C9 inhibitorNoYesNoYesCYP2D6 inhibitorYesYesNoYesCYP2D6 inhibitorYesYesYesYesCYP2D6 inhibitorYesYesYesYesDrug-likenessIipinski #violations000Ghose #violations0000Muegge #violations0000Bioavailability Score0.550.550.550.55PAINS #alerts1002Leadlikeness #violations0012Synthetic Accessibility3.163.192.843.29		Silicos-IT Solubility (mol/l)	1.50E-04	8.61E-07	3.61E-07	7.69E-07
PharmaceuticsGl absorption BBB permeantHigh NoHigh HighHigh HighHigh HighBBB permeantNoYesYesNoPgp substrateNoNoNoNoCYP1A2 inhibitorYesYesYesYesCYP2C19 inhibitorNoYesYesNoCYP2C19 inhibitorNoYesYesNoCYP2C19 inhibitorYesYesNoYesCYP2C19 inhibitorYesYesNoYesCYP2D6 inhibitorYesYesNoNoCYP2D6 inhibitorYesYesYesYesDrug-likenessIipinski #violations000Ghose #violations0000Bioavailability Score0.550.550.550.55PAINS #alerts1000Brenk #alerts1002Leadlikeness #violations0012Synthetic Accessibility3.163.192.843.29		Silicos-IT class	Soluble	Poorly	Poorly	Poorly
PharmaceuticsGl absorptionHighHighHighHighHighBBB permeantNoYesYesNoPgp substrateNoNoNoNoCYP1A2 inhibitorYesYesYesYesCYP2C9 inhibitorNoYesYesNoCYP2C9 inhibitorNoYesNoYesCYP2D6 inhibitorYesYesNoYesCYP2D6 inhibitorYesYesNoYesCYP2D6 inhibitorYesYesYesYesCYP2D6 inhibitorYesYesYesYesIpinski #violations0000Ghose #violations0000Keper #violations0000Bioavailability Score0.550.550.550.55PAINS #alerts1000Brenk #alerts1002Leadlikeness #violations0012.84				soluble	soluble	soluble
BBB permeantNoYesYesNoPgp substrateNoNoNoNoCYP1A2 inhibitorYesYesYesYesCYP2C9 inhibitorNoYesYesNoCYP2C9 inhibitorNoYesNoYesCYP2C9 inhibitorNoYesNoYesCYP2D6 inhibitorYesYesNoYesCYP2D6 inhibitorYesYesNoNoCYP2D6 inhibitorYesYesYesYesIg Kp (cm/s) (Skin permeation)-6.65-5.63-5.4-5.81Ipinski #violations0000Ghose #violations0000Keper #violations0000Bioavilability Score0.550.550.550.55PAINS #alerts1000Brenk #alerts0012Leadlikeness #violations0012	Pharmaceutics	GI absorption	High	High	High	High
Pgp substrateNoNoNoNoNoCYP1A2 inhibitorYesYesYesYesCYP2C19 inhibitorNoYesNoYesCYP2D6 inhibitorNoYesNoYesCYP2D6 inhibitorYesYesNoNoCYP2D6 inhibitorYesYesNoNoCYP2D6 inhibitorYesYesNoNoCYP2D6 inhibitorYesYesYesYesCYP2D6 inhibitorYesYesYesYesIpinski inhibitorYesYesYesYesIpinski infikitorYesYesYesYesUpinski infikitor0000Kipinski infikitor0000Veber infikitors0000KesViolations000Bioavailability Score0.550.550.550.55PAINS #alerts1002Leadlikeness iniolations0012Synthetic Accessibility3.163.192.843.29		BBB permeant	No	Yes	Yes	No
CYP1A2 inhibitorYesYesYesYesYesCYP2C19 inhibitorNoYesYesNoCYP2C9 inhibitorNoYesNoYesCYP2C9 inhibitorYesYesNoNoCYP2D6 inhibitorYesYesNoNoCYP3A4 inhibitorYesYesYesYeslog Kp (cm/s) (Skin permeation)-6.65-5.63-5.4-5.81Drug-likenessLipinski #violations000Gose #violations0000Keber #violations0000Bioavailability Score0.550.550.550.55PAINS #alerts1002Leadlikeness #violations0012Synthetic Accessibility3.163.192.843.29		Pgp substrate	No	No	No	No
CYP2C19 inhibitorNoYesYesNoCYP2C9 inhibitorNoYesNoYesCYP2D6 inhibitorYesYesNoNoCYP3A4 inhibitorYesYesYesYeslog Kp (cm/s) (Skin permeation)-6.65-5.63-5.4-5.81Drug-likenessLipinski #violations0000Ghose #violations00000Veber #violations00000Bioavilability Score0.550.550.550.550.55PAINS #alerts10000Brenk #alerts10021Leadlikeness #violations00123.163.192.843.29		CYP1A2 inhibitor	Yes	Yes	Yes	Yes
CYP2C9 inhibitorNoYesNoYesCYP2D6 inhibitorYesYesNoNoCYP3A4 inhibitorYesYesYesYeslog Kp (cm/s) (Skin permeation)-6.65-5.63-5.43-5.81Drug-likenessLipinski #violations0000Ghose #violations00000Veber #violations00000Bioavailability Score0.550.550.550.550.55PAINS #alerts10000Leadlikeness #violations0012Synthetic Accessibility3.163.192.843.29		CYP2C19 inhibitor	No	Yes	Yes	No
CYP2D6 inhibitorYesYesNoNoCYP3A4 inhibitorYesYesYesYesYeslog Kp (cm/s) (Skin permeation)-6.65-5.63-5.4-5.81Drug-likenessLipinski #violations000Ghose #violations0000Veber #violations0000Bioavilability Score0.550.550.550.55PAINS #alerts1000Brenk #alerts1002Leadlikeness #violations0012Synthetic Accessibility3.163.192.843.29		CYP2C9 inhibitor	No	Yes	No	Yes
CYP3A4 inhibitor Yes Yes Yes Yes log Kp (cm/s) (Skin permeation) -6.65 -5.63 -5.41 -5.81 Drug-likeness Lipinski #violations 0 0 0 0 Ghose #violations 0 0 0 0 0 Veber #violations 0 0 0 0 0 Kegge #violations 0		CYP2D6 inhibitor	Yes	Yes	No	No
log Kp (cm/s) (Skin permeation) -6.65 -5.63 -5.4 -5.81 Drug-likeness Lipinski #violations 0 0 0 0 Ghose #violations 0 0 0 0 0 Veber #violations 0 0 0 0 0 Bioavilability Score 0.55 0.55 0.55 0.55 PAINS #alerts 1 0 0 2 Leadlikeness #violations 0 0 1 2 Synthetic Accessibility 3.16 3.19 2.84 3.29		CYP3A4 inhibitor	Yes	Yes	Yes	Yes
Drug-likeness Lipinski #violations 0 0 0 0 0 Ghose #violations 0 0 0 0 0 0 Veber #violations 0 0 0 0 0 0 Egan #violations 0 0 0 0 0 0 Muegge #violations 0 0 0 0 0 0 Bioavailability Score 0.55 0.55 0.55 0.55 0.55 0.55 PAINS #alerts 1 0 0 2 2 Leadlikeness #violations 0 0 1 2 3.16 3.19 2.84 3.29		log Kp (cm/s) (Skin permeation)	-6.65	-5.63	-5.4	-5.81
Ghose #violations 0 0 0 0 Veber #violations 0 0 0 0 0 Egan #violations 0 0 0 0 0 Muegge #violations 0 0 0 0 0 Bioavailability Score 0.55 0.55 0.55 0.55 PAINS #alerts 1 0 0 2 Brenk #alerts 1 0 1 2 Synthetic Accessibility 3.16 3.19 2.84 3.29	Drug-likeness	Lipinski #violations	0	0	0	0
Veber #violations 0 0 0 0 Egan #violations 0 0 0 0 0 Muegge #violations 0 0 0 0 0 0 Bioavailability Score 0.55 0.55 0.55 0.55 0.55 0.55 PAINS #alerts 1 0 0 2 Brenk #alerts 1 0 2 2 Leadlikeness #violations 0 3.16 3.19 2.84 3.29		Ghose #violations	0	0	0	0
Egan #violations 0 0 0 0 Muegge #violations 0 0 0 0 Bioavailability Score 0.55 0.55 0.55 0.55 PAINS #alerts 1 0 0 0 Brenk #alerts 1 0 0 2 Leadlikeness #violations 0 1 2 Synthetic Accessibility 3.16 3.19 2.84 3.29		Veber #violations	0	0	0	0
Muegge #violations 0 0 0 0 Bioavailability Score 0.55 0.55 0.55 0.55 PAINS #alerts 1 0 0 0 Brenk #alerts 1 0 0 2 Leadlikeness #violations 0 0 1 2 Synthetic Accessibility 3.16 3.19 2.84 3.29		Egan #violations	0	0	0	0
Bioavailability Score 0.55 0.55 0.55 0.55 PAINS #alerts 1 0 0 0 Brenk #alerts 1 0 0 2 Leadlikeness #violations 0 0 1 2 Synthetic Accessibility 3.16 3.19 2.84 3.29		Muegge #violations	0	0	0	0
PAINS #alerts 1 0 0 0 Brenk #alerts 1 0 0 2 Leadlikeness #violations 0 0 1 2 Synthetic Accessibility 3.16 3.19 2.84 3.29		Bioavailability Score	0.55	0.55	0.55	0.55
Brenk #alerts 1 0 0 2 Leadlikeness #violations 0 0 1 2 Synthetic Accessibility 3.16 3.19 2.84 3.29		PAINS #alerts	1	0	0	0
Leadlikeness #violations 0 0 1 2 Synthetic Accessibility 3.16 3.19 2.84 3.29		Brenk #alerts	1	0	0	2
Synthetic Accessibility 3.16 3.19 2.84 3.29		Leadlikeness #violations	0	0	1	2
		Synthetic Accessibility	3.16	3.19	2.84	3.29

MAPK (Table 9), mTOR (Table 10), PI3K (Table 11), PIP5K1 α (Table 12), FGFR (Table 13), and CDK2 (Table 14) related to the parent article(1). Fig. 2 reports potency data analyzed from examination of the inhibitory activities of the selected, most active analogs compared to fisetin on the following kinases: A) c-Kit, B) CDK2/Cyclin A, C) CDK2/Cyclin E and D) mTOR. The attributes of IC₅₀ values (μ M) of calculated ranked inhibitor potency values are expressed as means \pm SD of three independent assays and are listed and described in Table 3 of the related research article

T	a	b	1	e	3

RMSD	values	obtained	after	Cross-	docking	for	the	selection	of	PDB	for	EGFR.

PDB ID Ligand	4LQM	3W2S	1M17	3W2R	4121	5XDL
4LQM	1.35	2.54	1.03	6.53	3.69	1.67
3W2S	5.85	1.65	2.05	6.18	4.82	1.35
1M17	1.37	2.42	0.49	2.47	3.31	2.59
3W2R	6.33	1.83	1.23	1.34	2.09	2.87
4I21	1.94	3.41	2.08	2.96	0.93	3.56
5XDL	1.25	4.36	1.69	3.51	1.87	2.41
Average	3.01	2.70	1.42	3.83	2.78	2.00

*average RMSD value showed best fitting for PDB ID: 1M17, which is selected for further study.

Table 4

RMSD values obtained after Cross-docking for the selection of PDB for c-Kit.

PDB ID						
Ligand	6GQM	6KLA	6XV9	6GQJ	6GQK	6GQL
6GQM	0.77	1.22	1.89	1.08	3.85	2.65
6KLA	1.02	2.61	2.71	1.25	2.29	1.48
6XV9	1.90	1.79	0.93	2.06	1.14	3.72
6GQJ	2.52	2.64	4.60	0.82	1.67	3.75
6GQK	3.03	2.29	2.27	1.52	1.10	2.77
6GQL	4.35	3.00	1.17	2.83	2.07	1.96
Average	2.26	2.25	2.26	1.54	2.02	2.72

* average RMSD value showed best fitting for PDB ID: 6GQJ, which is selected for further study.

Table 5

RMSD values obtained after Cross-docking for the selection of PDB for Akt.

PDB ID Ligand	3D0E	1H10	1UNQ	3096	2×39	2XH5
3D0E	1.72	2.80	4.07	5.78	3.96	3.45
1H10	5.58	1.54	3.98	6.18	5.14	5.89
1UNQ	3.95	4.57	1.49	4.27	4.83	3.26
3096	5.36	3.48	2.42	3.40	2.68	2.92
2×39	4.79	4.12	3.16	4.98	0.93	3.62
2XH5	3.85	5.45	3.76	5.46	2.28	1.38
Average	4.20	3.66	3.14	5.01	3.30	3.42

* average RMSD value showed best fitting for PDB ID:1UNQ, which is selected for further study.

Table 6

RMSD values obtained after Cross-docking for the selection of PDB for MET.

PDB ID Ligand	2WGJ	3CCN	3CD8	3DKF	3DKG	3F66	315N	3QTI	3U6H	5EYD	1R0P
2WGJ	0.77	8.2	0.89	1.08	1.51	_	0.84	2.42	11.37	0.84	9.09
3CCN	1.02	0.61	5.71	0.52	0.95	_	1.37	0.47	6.91	1.59	3.11
3CD8	0.90	5.79	1.83	0.68	2.31	7.27	0.62	0.79	6.71	0.63	5.99
3DKF	7.5	7.64	5.60	4.82	5.76	5.37	7.78	6.64	8.13	5.70	9.66
3DKG	4.03	5.29	7.27	5.25	_	2.67	8.74	7.21	_	6.88	9.11
3F66	10.35	9.00	7.71	3.98	6.07	_	7.67	8.25	12.07	7.66	11.49
3I5N	2.95	2.39	0.83	0.88	1.81	_	0.60	5.66	7.29	3.88	5.89
3QTI	_	_	7.06	_	7.16	_	_	_	7.99	10.72	_
3U6H	10.49	-	11.48	10.7	10.99	_	11.86	13.27	1.92	15.19	15.91
5EYD	0.89	0.83	0.96	0.94	1.40	_	0.96	0.86	7.82	0.61	7.35
1R0P	5.70	8.26	3.47	4.49	4.07	_	5.84	5.85	6.01	5.90	0.26
Average	4.46	4.51	4.61	3.33	4.20	_	4.62	5.12	7.62	5.42	7.78

*average RMSD value showed best fitting for PDB ID:3DKF, which is selected for further study.

RMSD values obta	ined after Cross-dock	ing for the selection o	of PDB for MEK1.		
PDB ID					
Ligand	3EQC	4LMN	3DV3	5EYM	4U81
3EQC	1.13	2.54	2.03	2.52	3.94
4LMN	1.55	1.21	1.46	1.86	4.18
3DV3	2.43	1.74	0.90	2.64	3.31
5EYM	3.26	3.68	1.42	1.44	2.28
4U81	1.88	1.92	2.86	3.32	0.93
Average	2.05	2.21	1.73	2.35	2.92

Table 7

* average RMSD value showed best fitting for PDB ID:3DV3, which is selected for further study.

Table 8

RMSD value obtained after re-docking for the selection of PDB for VEGFR1.

PDB ID Ligand	3HNG
3HNG	0.82

Table 9

RMSD values obtained after Cross-docking for the selection of PDB for MAPK.

PDB ID Ligand	1PME	60PH	3SA0	60PI	4ZXT	3W55	4QP2	5BUJ
1PME	1.05	2.45	2.03	1.86	3.68	2.77	3.99	2.94
60PH	1.58	1.20	1.58	1.98	2.89	4.31	2.83	2.51
3SA0	1.95	2.44	0.89	2.22	3.18	3.62	2.81	1.81
60PI	2.54	1.69	1.44	3.04	1.77	2.81	1.73	1.96
4ZXT	4.79	2.36	1.68	3.58	0.93	1.99	2.51	2.79
3W55	3.21	4.65	1.99	1.87	2.34	1.83	3.23	3.66
4QP2	2.68	2.18	1.37	2.65	1.73	2.63	1.51	3.75
5BUJ	3.18	2.66	3.12	3.69	2.47	2.39	1.97	1.35
Average	2.62	2.45	1.76	2.61	2.37	2.79	2.57	2.59

* average RMSD value showed best fitting for PDB ID:3SA0, which is selected for further study.

Table 10
RMSD value obtained after re-docking for the selection of PDB for mTOR.
PDB ID

Ligand	2NPU
2NPU	4.82

Table 11

RMSD values obtained after Cross-docking for the selection of PDB for PI3K.

PDB ID Ligand	4FAD	4FA6	4TV3	4TUU	60AC
4FAD	1.16	2.32	2.07	4.67	3.19
4FA6	1.85	1.44	2.02	3.06	4.14
4TV3	2.53	2.08	0.59	3.11	3.31
4TUU	2.49	1.91	1.62	1.36	2.75
60AC	4.79	3.34	1.38	2.49	0.93
Average	2.56	2.21	1.53	2.93	2.86

* average RMSD value showed best fitting for PDB ID:4TV3, which is selected for further study.

Table 12

RMSD val	ies obtained	after C	cross-docking	for the	selection	of PDB	for PIP5K1 α .
----------	--------------	---------	---------------	---------	-----------	--------	-----------------------

PDB ID Ligand	6CN3	6CN2	6CMW	5E3T	4TZ7	5E3S	5E3U
6CN3	0.87	2.80	2.59	1.08	2.11	3.37	1.48
6CN2	1.32	1.70	1.57	0.72	2.99	2.23	1.73
6CMW	1.89	3.97	1.75	0.88	2.21	1.27	2.62
5E3T	1.75	2.64	2.65	0.62	1.36	1.68	3.78
4TZ7	2.03	3.29	1.27	2.12	1.15	1.24	2.17
5E3S	3.51	2.90	1.17	3.98	3.03	1.38	2.27
5E3U	2.59	1.93	3.83	0.89	1.61	2.42	1.70
Average	1.99	2.74	2.11	1.47	2.06	1.94	2.25

*average RMSD value showed best fitting for PDB ID:5E3T, which is selected for further study.

Table 13

RMSD values obtained after Cross-docking for the selection of PDB for FGFR.

PDB ID						
Ligand	4UWC	5AM6	5EW8	5AM7	4UXQ	4WUN
4UWC	1.37	2.33	2.91	3.73	1.69	2.76
5AM6	1.85	2.01	2.41	1.86	3.26	1.87
5EW8	1.95	3.11	1.39	2.71	3.81	3.36
5AM7	2.19	1.81	2.57	1.63	1.89	2.43
4UXQ	3.94	2.61	1.61	1.87	0.93	1.97
4WUN	2.83	2.37	2.26	2.93	4.57	1.55
Average	2.35	2.37	2.19	2.45	2.69	2.32

* average RMSD value showed best fitting for PDB ID:5EW8, which is selected for further study.

 Table 14

 RMSD values obtained after Cross-docking for the selection of PDB for CDK2.

PDB ID Ligand	1B39	1GIJ	1GII	2DUV	1GIH	2C5Y	1B38	3PXY	6INL	4EZ3	6GUH
1B39	1.22	2.81	1.89	1.08	1.51	1.44	0.84	2.42	5.37	0.84	5.09
1GIJ	2.01	1.16	1.57	0.52	0.95	1.87	1.37	0.47	4.91	1.59	1.21
1GII	1.92	1.79	3.18	0.68	2.31	5.27	2.62	0.79	3.71	0.63	3.99
2DUV	2.25	3.64	2.46	2.82	3.76	3.37	3.78	4.64	5.13	3.70	5.43
1GIH	3.04	_	2.72	3.25	_	2.67	6.74	5.21	_	4.88	4.21
2C5Y	3.51	_	2.17	1.98	4.07	_	3.67	6.25	6.07	4.66	4.49
1B38	_	3.92	1.83	0.88	1.81	3.59	2.60	3.66	3.29	3.88	3.89
3PXY	2.59	3.29	2.06	_	5.16	1.66	_	_	4.99	4.72	_
6INL	4.19	3.11	5.48	4.72	4.99	3.96	4.86	7.27	1.92	1.19	3.72
4EZ3	0.89	1.38	1.06	0.94	1.40	-	4.96	0.86	2.82	0.61	3.13
6GUH	2.50	3.62	3.47	2.49	2.07	2.64	3.84	3.85	3.01	3.90	0.46
Average	2.41	2.74	2.53	1.9	2.8	2.94	3.60	3.54	4.12	2.78	3.56

* average RMSD value showed best fitting for PDB ID:2DUV, which is selected for further study.

[1]. Fig. 3 reports the mean western blot bands (A-B) and their corresponding densitometric data analysis in bar graph format (C-D) of the different melanoma (A375) and non-melanoma (A431) cells treated in the presence or absence of test analogs **F9** and **F17**, showing the differential expression of apoptosis induction via activation of the extrinsic and intrinsic apoptotic pathways. The data for **F20** are described in the related research article [1]. Fig. 4 summarizes the Western blot band results (A-B) and the Bar graph plots data (C-D) from the analysis of the effects of different concentrations of flavonol analogs **F9** and **F17** on the protein expression levels of cyclin A2, cyclin E2, CDK2, phosphorylated c-Kit and Stat3 in 48h treated A375 and A431 skin cancer cells. In Fig. 5, the Western blot bands (Upper panel) and the Bar graph plots (lower panels) exhibit analyzed data from the effects of different concentrations of analogs **F9** and **F17** on the protein expression levels of phosphorylated p90RSK/Akt/mTOR/MAPK (ERK1/2) and ribosomal



Fig. 2. Potent flavonol analogs significantly inhibit c-Kit, CDK2, and mTOR kinase activities. Data from the determination of kinase inhibitory activity and IC₅₀ values for potent flavonol analogs and fisetin. IC₅₀ values (μ M) calculated for potent inhibitors of: A) c-Kit, B) CDK2/Cyclin A, C) CDK2/Cyclin E and D) mTOR. Values are expressed as means \pm SD of three independent assays, and all graphs were made using the GraphPad Prism program suite.



Fig. 3. (A-B). Potent flavonol analogs induce apoptosis through activation of the extrinsic and intrinsic apoptotic pathways in melanoma and non-melanoma cells. Effect of different concentrations of flavonol analogs F9 and F17 on the protein expression levels of markers of apoptosis including pro- and cleaved caspase-3, -7 and -8, PARP (116 kDa) and cleaved PARP (85 kDa), as well as Bcl-2 family of proteins (Bax and Bcl-2), components of the intrinsic apoptosis pathway in 48h treated A375 and A431 cells. A375 and A431 cells were incubated in the absence or presence of flavonol analogs (F9 and F17; 0, IC_{50} , 2xIC_{50} ; μ M, 48h), and the whole-cell lysates of cells treated with/without F9 and F17 were subjected to SDS-polyacrylamide gel electrophoresis. Equal protein loading was confirmed by reprobing for β -actin or vinculin as loading control, and the actual protein levels were normalized to the loading control and expressed as percentage. The Western blot data shown are representative of immunoblot of more than two independent experiments with similar results.

Fig. 3 (C-D). Potent flavonol analogs F9 and F17 induce apoptosis through activation of the extrinsic and intrinsic apoptotic pathways in melanoma and non-melanoma cells as shown graphically. The data expressed as the percentage of which analogs F9 and F17 significantly suppressed the protein expression levels of pro-and-cleaved caspases (3,7 and -8), PARP (116 kDa) and cleaved PARP (85 kDa), as well as Bax and Bcl-2 in (C) A375 and (D) A431 as compared with untreated control cells. Bar graphs represent mean \pm SD of results of relative quantitative density values for the blots normalized with an internal loading control from three independent experiments. The statistical significance was determined using one-way ANOVA and Dunn's multiple comparison test, and p < 0.05 (*) was considered significant.



Fig. 3. Continued

protein S6 in A375 melanoma and A431 non-melanoma skin cancer cells after 48h treatment. The supplementary raw data are available in in the link. Fig. 6 reports the micrographic photo images (A-B) and the mean values (C-D) from the analysis of the dose-dependent effects of the analogs **F9** and **F17** on the wound closure into the initial cell-free areas compared to the percentage of the cell-free areas (A) A375 and (B) A431, in contrast to untreated control cells, after 48 h of incubation (see supplementary raw data files are available at the link). Fig. 7 describes the data from the determination of the long-term dose-dependent effect of the analogs **F9** and **F17** on the percentage of colonies when compared to the respective untreated cutaneous carcinoma control cell lines. All the data for compound **F20** are displayed in the associated/parent research article [1]. The supplementary raw data files are available in the link.

2. Experimental Design, Materials and Methods

This study's major purpose was to validate the newly synthesized and fully characterized flavonol analogs [4], as anticancer agents, with different effects on basal and squamous carcinoma of the skin cells *in vitro*. Inclusion criteria included in the supplementary datasets were not extensively presented in the associated article. These data complement and further enhance the results presented in the associated article [1]. These datasets and their analyses aimed at improving our understanding of the physicochemical and other pharmaceutical properties of the compounds *in vitro* were explored through the use of the online SWISS-ADME platform of the Swiss Institute of Bioinformatics (http://www.swissadme.ch) [3], and compared with the same



Fig. 4. Potent flavonol analogs F9 and F17 inhibit the protein expression levels of cyclin A/E, CDK2 and phosphorylated c-Kit and Stat3 in A375 melanoma and A431 non-melanoma cells. Effect of different concentrations of flavonol analogs F9 and F17 on the protein expression levels of cyclin A2, cyclin E2, CDK2, phosphorylated c-Kit and Stat3 in 48h treated (A) A375 and (B) A431 cells. A375/A431 cells were incubated with/without analogs (F9 and F17; 0, IC₅₀, zxlC₅₀; μ M, 48h), and western blotting performed as described in the method section. Equal protein loading was confirmed by reprobing for β -actin as loading control, and protein levels were normalized to the loading control and expressed as percentage. The Western blot data shown are representative of immunoblots of three independent experiments with similar results. (C and D) The data expressed in the Bar graphs represent mean \pm SD of relative quantitative normalized density values in percentage with an internal loading control from three independent experiments. The analogs F9 and F17 significantly suppressed the protein expression levels of these in (C) A375 and (D) A431 as compared with untreated control cells. For bar graphs, the statistical significance was determined using one-way ANOVA and Dunn's multiple comparison test, and p < 0.05 (*) was considered significant.

descriptors obtained for fisetin, the reference compound. A detailed description of the procedures of study-specific investigation and the molecular and cellular assay protocols are essentially as presented in the related research article [1]. Equal protein loading was confirmed by reprobing for β -actin or vinculin as a loading control, and the actual protein levels were normalized to the loading control and expressed as a percentage. The Western blot data shown are representative of immunoblot of more than two independent experiments with similar results. Statistical analysis was conducted, and graphics were designed using GraphPad PRISM program suite, version 8 (GraphPad Software, Inc., La Jolla, CA, USA). The data expressed in the Bar graphs represent mean \pm SD of values in percentage control from three independent experiments; the statistical significance was determined using one-way ANOVA and Bonferoni's multiple compar-



Fig. 5. Potent flavonol analogs F9 and F17 inhibit the protein expression levels of phosphorylated p90RSK/Akt/mTOR/MAPK (ERK1/2) and ribosomal protein S6 in A375 melanoma and A431 non-melanoma cells. Role of the flavonol analogs F9 and F17 on the protein expression levels of cyclin A2, cyclin E2, CDK2, phosphorylated Akt, p90RSK, mTOR, MAPK (ERK1/2) and ribosomal protein in 48h treated (A) A375 and (B) A431 cells. A375/A431 cells were incubated with/without analogs (F9 and F17; 0, IC₅₀, $2xlC_{50}$; μ M, 48h), and western blotting performed as described in method section. Equal protein loading was confirmed by reprobing for β -actin as loading control, and protein levels were normalized to the loading control and expressed as percentage. The Western blot data shown are representative of immunoblot of three independent experiments with similar results (C and D). The data expressed in the Bar graphs represent mean \pm SD of relative quantitative normalized density values in percentage with an internal loading control from three independent experiments. The analogs F9 and F17 significantly suppressed the protein expression levels of these in (C) A375 and (D) A431 as compared with untreated control cells. For bar graphs, the statistical significance was determined using one-way ANOVA and Dunn's multiple comparison test, and p < 0.05 (*) was considered significant.



Fig. 6. Potent flavonol analogs F9 and F17 inhibit Scratch Wound Healing in 2D cultures of A375 and A431. Effect of the flavonol analogs **F9 and F17** on the wound closure into the initial cell-free areas compared to the percentage of cell-free areas (A) A375 and (B) A431 cells. (C and D) significant dose-dependent decrease in cultured cells' scratch wound healing areas was observed in the presence of selected potent flavonol hits, compared to untreated control cells, after 48 h of incubation. The data expressed in the Bar graphs represent mean \pm SD of scratched wound area values in percentage compared to 0 hcontrol and 24h controls from three independent experiments. The analogs **F9 and F17** significantly suppressed wound healing area (C) A375 and (D) A431 as compared with untreated control cells. The statistical significance was determined using one-way ANOVA and Dunn's multiple comparison test, and p < 0.05 (*) was considered significant.



Fig. 7. Potent flavonol analogs F9 and F17 inhibit colony formation in 2D cultures of A375 and A431. (A-D) Longterm effect of the potent flavonol analogs on clonogenic potential in (A) A375, and (B) A431 cells. Treatment with analogs F9 and F17 ($\frac{1}{2}$ IC₅₀, IC₅₀ and 2xIC₅₀ μ M of the respective cell lines), significantly reduced/suppressed the percentage of colonies in a dose-dependent manner when compared to the respective control untreated cutaneous carcinoma cells. (C and D) The data expressed in the Bar graphs represent mean \pm SD of values in percentage control from threeindependent experiments, the statistical significance was determined using one-way ANOVA and Bonferoni's multiple comparison test, and p < 0.05 (*) was considered significant.

ison test or Dunn's multiple comparison test. P-values \leq 0.05 were considered statistically significant.

Ethics Statement

The primary normal human epidermal keratinocytes used were isolated from new born foreskin biopsies or adult skin biopsies and established in culture using published protocols, [5], and were obtained under a University of Wisconsin–Madison-approved institutional review board protocol. The experiments were conducted following the Declaration of Helsinki principles.

CRediT Author Statement

Tithi Roy: Methodology, Investigation, Writing - Original draft Preparation, Writing review & editing; Samuel T. Boateng: Methodology, Investigation, Writing - review & editing; Sergette Banang-Mbeumi: Methodology, Investigation, Writing - review & editing; Pankaj K. Singh: Methodology, Investigation, Formal analysis, Writing – review & editing; Pratik Basnet: Methodology, Investigation, Formal analysis, Writing - review; Roxane-Cherille N. Chamcheu: Methodology, Investigation, Writing - review & editing Federico Ladu: Methodology, Investigation, Writing & review; Isabel Chauvin: Methodology and Investigation; Vladimir S. Spiegelman: Resources, Formal analysis, Writing – review & editing; Ronald A. Hill: Investigation, Formal analysis, Writing - review & editing; Konstantin G. Kousoulas: Investigation, supervision, Resources, Writing - review & editing. Bolni Marius Nagalo: Methodology, Investigation, supervision, Writing - review & editing; Anthony L. Walker: Methodology, Investigation, supervision, Writing - review & editing; Jean Fotie: Methodology, Investigation, Writing - Original draft Preparation, Writing - review & editing; Siva Murru: Methodology, Investigation, supervision, Resources, Writing - review & editing; Mario Sechi: Methodology, Investigation, supervision, Resources, Writing – Original draft Preparation, Writing – review & editing; Jean Christopher Chamcheu: Conceptualization, Methodology, Investigation, Resources, Formal analysis, Writing -Original draft Preparation, Writing - review & editing, supervision, Visualization.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships which have or could be perceived to have influenced the work reported in this article.

Acknowledgments

This reported work was supported in part by a start-up fund and a Faculty Research Seed grant 5CALHN-260615 from the University of Louisiana-Monroe College of Pharmacy (to JCC), LBRN Pilot research grant Awards (to JCC and SM) from an IDeA Networks of Biomedical Research Excellence (INBRE) award from the National Institute of General Medical Sciences of the National Institutes of Health (NIGMS/NIH) grant number P2O GM103424-18 (to KGK), and an LBRN-INBRE-COBRE Administrative Supplement Award (to JCC) from NIGMS/NIH grant 3P20GM103424-18S1 (to KGK). Spectrometric data were acquired from instruments located at the Louisiana Tech NMR facility funded by grant # LEQSF(2019-20)-ENH-DE-10 obtained from the Louisiana Board of Regents and the College of Engineering and Science at Louisiana Tech. MS thanks the Fondazione di Sardegna for its partial support, and is also grateful to the Schrödinger Team for the opportunity to evaluate a trial of the latest version of software Maestro.

Supplementary Materials

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.dib.2021.106858.

References

- [1] T Roy, ST Boateng, S Banang-Mbeumi, PK Singh, P Basnet, R-CN Chamcheu, et al., Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers, Bioorg Chem 107 (2020 Dec) 104595.
- [2] JC Chamcheu, S Esnault, VM Adhami, AL Noll, S Banang-Mbeumi, T Roy, et al., Fisetin, a 3,7,3',4'-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models, Cells 8 (9) (2019 Sep).
- [3] A Daina, O Michielin, V. Zoete, SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci Rep. 7 (2017 Mar) 42717.
- [4] A Rani, A Anand, K Kumar, V. Kumar, Recent developments in biological aspects of chalcones: the odyssey continues, Expert Opin Drug Discov 14 (3) (2019 Mar) 249–288.
- [5] JC Chamcheu, HC Pal, IA Siddiqui, VM Adhami, S Ayehunie, BT Boylan, et al., Prodifferentiation, anti-inflammatory and antiproliferative effects of delphinidin, a dietary anthocyanidin, in a full-thickness three-dimensional reconstituted human skin model of psoriasis, Skin Pharmacol Physiol 28 (4) (2015) 177–188.